Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-13 1:34 pm Sale | 13G | Prelude Therapeutics Incorporated PRLD | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0 0.000% | -2,507,992 (Position Closed) | View |
| 2024-02-12 5:30 pm Purchase | 13G | Prelude Therapeutics Incorporated PRLD | Flynn James E | 4,133,000 9.850% | 910,310 (+28.25%) | View |
| 2024-02-12 4:26 pm Purchase | 13G | Prelude Therapeutics Incorporated PRLD | Vaddi Krishna | 4,908,086 11.100% | 608,763 (+14.16%) | View |
| 2024-01-10 08:53 am Sale | 13G | Prelude Therapeutics Incorporated PRLD | FMR LLC | 264,686 0.630% | -4,613,865 (-94.57%) | View |
| 2023-12-13 4:55 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | BAKER BROS. ADVISORS LP | 10,222,968 24.300% | 3,888 (+0.04%) | View |
| 2023-11-13 08:30 am Purchase | 13G | Prelude Therapeutics Incorporated PRLD | Flynn James E | 3,222,690 7.680% | 3,222,690 (New Position) | View |
| 2023-05-24 4:47 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 15,716,642 28.600% | 869,565 (+5.86%) | View |
| 2023-05-24 4:31 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | BAKER BROS. ADVISORS LP | 10,219,080 19.500% | 92,663 (+0.92%) | View |
| 2023-02-13 10:52 am Purchase | 13G | Prelude Therapeutics Incorporated PRLD | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,507,992 5.240% | 2,507,992 (New Position) | View |
| 2023-02-10 09:08 am Purchase | 13G | Prelude Therapeutics Incorporated PRLD | FMR LLC | 4,878,551 10.193% | 288,960 (+6.30%) | View |
| 2023-02-10 08:00 am Purchase | 13G | Prelude Therapeutics Incorporated PRLD | Vaddi Krishna | 4,299,323 11.300% | 680,770 (+18.81%) | View |
| 2023-02-09 12:31 pm Sale | 13G | Prelude Therapeutics Incorporated PRLD | FMR LLC | 4,589,591 9.589% | -1,349,341 (-22.72%) | View |
| 2022-02-09 10:24 am Sale | 13G | Prelude Therapeutics Incorporated PRLD | FMR LLC | 5,938,932 12.578% | -413,049 (-6.50%) | View |
| 2022-02-04 4:05 pm Purchase | 13G | Prelude Therapeutics Incorporated PRLD | Vaddi Krishna | 3,618,553 9.700% | 680,781 (+23.17%) | View |
| 2021-02-11 4:06 pm Purchase | 13G | Prelude Therapeutics Incorporated PRLD | Vaddi Krishna | 2,937,772 12.620% | 2,937,772 (New Position) | View |
| 2021-02-10 09:23 am Purchase | 13G | Prelude Therapeutics Incorporated PRLD | FMR LLC | 6,351,981 13.747% | 2,142,018 (+50.88%) | View |
| 2021-02-08 10:31 am Purchase | 13G | Prelude Therapeutics Incorporated PRLD | FMR LLC | 4,209,963 9.633% | 4,209,963 (New Position) | View |
| 2021-01-29 4:48 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | BAKER BROS. ADVISORS LP | 10,126,417 28.800% | 5,189 (+0.05%) | View |
| 2021-01-13 5:34 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 14,847,077 31.900% | 41,700 (+0.28%) | View |
| 2020-10-05 5:17 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 14,805,377 33.900% | 14,805,377 (New Position) | View |